GRAZIANI, GRAZIA
 Distribuzione geografica
Continente #
NA - Nord America 76.211
EU - Europa 6.741
AS - Asia 1.344
SA - Sud America 39
Continente sconosciuto - Info sul continente non disponibili 13
AF - Africa 10
OC - Oceania 9
Totale 84.367
Nazione #
US - Stati Uniti d'America 76.148
IT - Italia 1.703
UA - Ucraina 1.144
DE - Germania 1.056
CN - Cina 845
IE - Irlanda 747
FR - Francia 589
SE - Svezia 414
GB - Regno Unito 315
PL - Polonia 307
KR - Corea 291
FI - Finlandia 230
RU - Federazione Russa 95
JP - Giappone 56
CA - Canada 43
IN - India 42
BE - Belgio 27
CZ - Repubblica Ceca 23
NL - Olanda 23
IR - Iran 22
BR - Brasile 19
MX - Messico 18
VN - Vietnam 18
EU - Europa 12
KG - Kirghizistan 12
HK - Hong Kong 11
IL - Israele 11
AT - Austria 9
SG - Singapore 9
AL - Albania 8
BG - Bulgaria 8
CH - Svizzera 8
CO - Colombia 8
AU - Australia 7
CL - Cile 7
ES - Italia 7
MK - Macedonia 5
PH - Filippine 5
DK - Danimarca 4
ID - Indonesia 4
PT - Portogallo 4
RO - Romania 4
TR - Turchia 4
TW - Taiwan 4
AR - Argentina 3
EG - Egitto 3
LU - Lussemburgo 3
AE - Emirati Arabi Uniti 2
GR - Grecia 2
HU - Ungheria 2
MA - Marocco 2
MW - Malawi 2
MY - Malesia 2
NZ - Nuova Zelanda 2
A1 - Anonimo 1
BD - Bangladesh 1
CY - Cipro 1
DZ - Algeria 1
EC - Ecuador 1
GT - Guatemala 1
IQ - Iraq 1
JM - Giamaica 1
LT - Lituania 1
MD - Moldavia 1
MU - Mauritius 1
NO - Norvegia 1
PE - Perù 1
PS - Palestinian Territory 1
SA - Arabia Saudita 1
SC - Seychelles 1
SI - Slovenia 1
UZ - Uzbekistan 1
Totale 84.367
Città #
Woodbridge 24.329
Wilmington 19.893
Houston 19.875
Ann Arbor 2.050
Fairfield 1.618
Chandler 1.071
Jacksonville 1.015
Ashburn 943
Dublin 694
Seattle 639
Cambridge 549
Medford 533
Dearborn 451
New York 445
Beijing 393
Rome 335
Kraków 301
Lawrence 257
Mülheim 176
Milan 133
Menlo Park 127
San Diego 90
Zhengzhou 90
Boardman 60
Mountain View 56
Redwood City 55
University Park 53
Falls Church 47
Nanjing 40
Norwalk 40
Palo Alto 40
Hefei 38
San Mateo 37
Guangzhou 30
London 29
Verona 28
Brussels 26
Civitavecchia 26
Hangzhou 26
Shanghai 26
Phoenix 24
Engelhard 21
Kunming 21
Prague 21
Pisa 20
Saint Petersburg 20
Seoul 19
Toronto 19
Naples 18
Ottawa 18
Catania 16
Nanchang 15
Napoli 15
Pune 15
Del Norte 14
Dong Ket 14
Florence 14
Fuzhou 14
Jinan 14
Nürnberg 14
Indiana 13
Helsinki 12
Kansas City 12
Turin 12
Bari 11
Hebei 11
Redmond 11
Chicago 10
Kilburn 10
Palermo 10
Washington 10
Casalnuovo Di Napoli 9
San Jose 9
Bologna 8
Center 8
Chengdu 8
Creede 8
Shenyang 8
Auburn Hills 7
Changsha 7
Council Bluffs 7
La Veta 7
Padova 7
Paris 7
Pavia 7
Pioppi 7
Segrate 7
Arnesano 6
Cattolica 6
Gragnano 6
Hong Kong 6
Los Angeles 6
Salt Lake City 6
San Francisco 6
St. George 6
São Paulo 6
Tappahannock 6
Tehran 6
Trieste 6
Wuhan 6
Totale 77.331
Nome #
Gli inibitori della poli (ADP-ribosio) polimerasi (PARP) per superare la chemioresistenza a metilanti e inibitori di topoisomerasi I 999
Parte V- Farmaci per il trattamento di infezioni, tumori e malattie immunologiche; Capitoli: 49, Principi di chemioterapia antimicrobica; 50, Farmaci antibatterici; 51, Farmaci antivirali; 52, Farmaci antifungini; 53, Farmaci antiprotozoari; 54, Farmaci anti-elmintici; 55, Farmaci antitumorali. Farmacologia, VII edizione Italiana di Rang and Dale's Pharmacology (VII ed. Inglese); p.616-680. 625
Valproic acid increases the stimulatory effect of estrogens on proliferation of human endometrial adenocarcinoma cells 467
Targeted therapy for brain tumours: role of PARP inhibitors 459
Inhibition of homologous recombination by treatment with BVDU (brivudin) or by RAD51 silencing increases chromosomal damage induced by bleomycin in mismatch repair-deficient tumour cells 452
A novel method for monitoring response to chemotherapy based on the detection of circulating cancer cells: a case report 449
Combined effects of adenovirus-mediated wild-type p53 transduction, temozolomide and poly (ADP-ribose) polymerase inhibitor in mismatch repair deficient and non-proliferating tumor cells 441
Poly(ADP-ribose) polymerase inhibitor increases growth inhibition and reduces G2/M cell accumulation induced by temozolomide in malignant glioma cells 435
Common fragile sites in colon cancer cell lines: role of mismatch repair, RAD51 and poly(ADP-ribose) polymerase-1 435
Beneficial and Detrimental Effects of Antiretroviral Therapy on HIV-Associated Immunosenescence 434
Bacillus Calmette-Guerin down-regulates CD1b induction by granulocyte-macrophage colony stimulating factor in human peripheral blood monocytes 432
Poly(ADP-ribose) glycohydrolase inhibitor as chemosensitiser of malignant melanoma for temozolomide 431
Stable depletion of poly (ADP-ribose) polymerase-1 reduces in vivo melanoma growth and increases chemosensitivity 428
Doping with growth hormone/IGF-1, anabolic steroids or erythropoietin: is there a cancer risk? 428
INVECCHIAMENTO, IMMUNITÀ E FARMACI 428
VIII edizione Rang & Dale's Pharmacology, edizione italiana Rang & Dale Farmacologia Edra LSWR Edizioni 9788821440397. 425
BCG-infected adherent mononuclear cells release cytokines that regulate group 1 CD1 molecule expression 424
Valproic acid activity in androgen-sensitive and -insensitive human prostate cancer cells 422
BRCA1, PARP1 and γH2AX in acute myeloid leukemia: Role as biomarkers of response to the PARP inhibitor olaparib. 422
The integrin antagonist cilengitide increases the antitumor activity of temozolomide against malignant melanoma 421
Temozolomide: An Update on Pharmacological Strategies to Increase its Antitumour Activity 420
Combined treatment with temozolomide and poly(ADP-ribose) polymerase inhibitor enhances survival of mice bearing hematologic malignancy at the central nervous system site 418
Poly(ADP-ribose) polymerase signaling of topoisomerase 1-dependent DNA damage in carcinoma cells 418
Exogenous Control of the Expression of Group I CD1 Molecules Competent for Presentation of Microbial Nonpeptide Antigens to Human T Lymphocytes 417
Rifampin increases cytokine-induced expression of the CD1b molecule in human peripheral blood monocytes 414
Challenging resistance mechanisms to therapies for metastatic melanoma 413
Treatment with temozolomide and poly(ADP-ribose) polymerase inhibitors induces early apoptosis and increases base excision repair gene transcripts in leukemic cells resistant to triazene compounds 412
Cisplatin increases sensitivity of human leukemic blasts to triazene compounds 409
Cilengitide down-modulates invasiveness and vasculogenic mimicry of neuropilin-1 expressing melanoma cells through the inhibition of αvβ5 integrin. 409
Exploiting Microglial Functions for the Treatment of Glioblastoma 409
Clinical perspectives of PARP inhibitors 408
Decline of natural cytotoxicity of human lymphocytes following infection with human T-cell leukemia/lymphoma virus (HTLV) 407
A new water soluble MAPK activator exerts antitumor activity in melanoma cells resistant to the BRAF inhibitor vemurafenib 407
Oral administration of PARP inhibitor GPI 18180 increases the anti-tumor activity of temozolomide against intracranial melanoma in mice. 406
In vitro infection of CD4+ T lymphocytes with HTLV-I generates immortalized cell lines coexpressing lymphoid and myeloid cell markers 406
Immunopharmacology of antitumor agents. 406
Apoptotic and genotoxic effects of a methyl sulfonate ester that selectively generates N3-methyladenine and poly(ADP-ribose) polymerase inhibitors in normal peripheral blood lymphocytes 405
Adjuvant treatment of breast cancer: a pilot immunochemotherapy study with CMF, interleukin-2 and interferon alpha 405
Cytokine-induced expression of CD1b molecules by peripheral blood monocytes: influence of 3'-azido-3'-deoxythymidine 405
Effect of prostaglandin A1 on proliferation and telomerase activity of human melanoma cells in vitro 405
Ellagic acid inhibits bladder cancer invasiveness and in vivo tumor growth 405
null 404
Staurosporine increases carcinoembryonic antigen expression in a human colon cancer cell line 403
Detection of circulating tumor cells is improved by drug-induced antigen up-regulation: preclinical and clinical studies 401
Treatment of peripheral blood with staurosporine increases detection of circulating carcinoembryonic antigen positive tumor cells 401
Effects of single or split exposure of leukemic cells to temozolomide, combined with poly(ADP-ribose) polymerase inhibitors on cell growth, chromosomal aberrations and base excision repair components 400
Cytokine-induced expression of CD1b molecules by peripheral blood monocytes: Influence of 3'-azido-3'-deoxythymidine 400
Mutation of the mismatch repair gene hMSH2 and hMSH6 in a human T-cell leukemia line tolerant to methylating agents 399
Brain distribution and efficacy as chemosensitizer of an oral formulation of PARP-1 inhibitor GPI 15427 in experimental models of CNS tumors. 398
Trattato di Medicina Interna Gasbarrini G. Volume 3 398
Influence of bacillus calmette-guerin (BCG) on induction of antigen-presenting cd1b molecule by granulocyte- macrophage colony stimulating factor (GM-CSF). 398
Triazene compounds induce apoptosis in O6-alkylguanine-DNA alkyltransferase deficient leukemia cell lines 396
A novel water-soluble nitrobenzoxadiazole is highly effective against vemurafenib-resistant human melanoma cells 396
Role of the mismatch repair system and p53 in the clastogenicity and cytotoxicity induced by bleomycin 395
Decline in telomerase activity as a measure of tumor cell killing by antineoplastic agents in vitro 395
Pharmacological strategies to increase the antitumor activity of methylating agents 394
Effect of hydrocortisone on human natural killer activity and its modulation by beta interferon 394
Potential clinical applications of poly(ADP-ribose) polymerase (PARP) inhibitors 393
Parte V- Farmaci per il trattamento di infezioni, tumori e malattie immunologiche (capitoli 49, 50, 51, 52, 53, 54, 55) Farmacologia VII edizione Italiana di Rang and Dale's Pharmacology (VII ed. Inglese). p. 616-680. 393
5(2-bromovinyl)-2’-deoxyuridine (BVDU), increases the amount of chromatid breaks induced by bleomycin in mismatch repair deficient tumor cells by inhibiting homologous recombination 391
Valproic acid inhibits proliferation and affects androgen sensitività in prostatic cancer cells 390
Attenuation of O(6)-methylguanine-DNA methyltransferase activity and mRNA levels by cisplatin and temozolomide in jurkat cells 388
Telomerase as a potential anticancer target: growth inhibition and genomic instability 386
Antigenic changes induced in tumor cells in vivo by dimethil-imidazole carboxamide (DTIC) 386
Type 5 phosphodiesterase regulates glioblastoma multiforme aggressiveness and clinical outcome 385
Inhibition of telomerase increases resistance of melanoma cells to temozolomide, but not to temozolomide combined with poly (ADP-ribose) polymerase inhibitor 384
Novel Glutathione S-Transferase Inhibitor Enhances Temozolomide Efficacy Against Malignant Melanoma 52nd Annual Meeting of the Italian Cancer Society. Lost in translation: bridging the gap between cancer research and effective therapies 384
I FARMACI E LA FRAGILITA’ 384
Primary cultures of microglial cells for testing toxicity of anticancer drugs. 382
Pharmacological modulation of carcinoembryonic antigen in human cancer cells: studies with staurosporine 382
Poly (ADP-ribose) polymerase (PARP) inhibition or PARP-1 gene deletion reduces angiogenesis 382
Poly(ADP-ribose) polymerase (PARP) inhibition or PARP-1 gene deletion reduces angiogenesis 381
Effect of the combined treatment with 5-fluorouracil, gamma-interferon or folinic acid on carcinoembryonic antigen expression in colon cancer cells 380
Emergence of double-positive CD4/CD8 cells from adult peripheral blood mononuclear cells infected with human T cell leukemia virus type I (HTLV-I) 380
In vitro infection of leukemic bone marrow with HTLV-I generates immortalized cell lines expressing T or myeloid cell phenotype 379
Inhibition of O-6-alkylguanine DNA-alkyltransferase or poly(ADP-ribose) polymerase increases susceptibility of leukemic coils to apoptosis induced by temozolomide 379
Effect of rifampin on CD1b expression and double-negative T cell responses against mycobacteria-derived glycolipid antigen 378
PARP-1 inhibition to treat cancer, ischemia, inflammation 378
Monoclonal antibodies to CTLA-4 with focus on ipilimumab 378
Role of PARP, NF-kB and telomerase in necrosis induced by selective methylation of N3-adenine. 377
Role of DNA repair pathways in the control of common fragile sites expression. 377
A region of proto-dbl essential for its transforming activity shows sequence similarity to a yeast cell cycle gene, CDC24, and the human breakpoint cluster gene, bcr 377
Mutations of human DNA topoisomerase I at poly(ADP-ribose) binding sites: modulation of camptothecin activity by ADP-ribose polymers. 376
Decline in telomerase activity as a measure of tumor cell killing by antineoplastic agents in vitro 374
Influence of Mycobacterium bovis bacillus Calmette Guérin on in vitro induction of CD1 molecules in human adherent mononuclear cells 373
Influence of MLH1 on colon cancer sensitivity to poly(ADP-ribose) polymerase inhibitor combined with irinotecan. 373
Neuropilin-1 as Therapeutic Target for Malignant Melanoma. 373
Pharmacological inhibition of poly(ADP-ribose) polymerase activity down-regulates the expression of syndecan-4 and Id-1 in endothelial cells 372
Ipilimumab: A novel immunostimulatory monoclonal antibody for the treatment of cancer 372
NF-κB is activated in response to temozolomide in an AKT-dependent manner and confers protection against the growth suppressive effect of the drug. 372
Neuropilin-1 expressing melanoma cells as a model to study the aggressiveness of metastatic melanoma 372
5-Fluorouracil increases carcinoembryonic antigen expression and shedding in colon cancer cell clones with different basal levels of the molecule 371
Chimeric molecules between keratinocyte growth factor and basic fibroblast growth factor define domains that confer receptor binding specificities 371
High-dose ascorbate and arsenic trioxide selectively kill acute myeloid leukemia and acute promyelocytic leukemia blasts in vitro 371
VEGFR-1 derived peptide specifically inhibits PlGF and VEGF-B-induced migration of endothelial cells and in vivo angiogenesis. 369
Evidence that corticotropin-releasing hormone inhibits cell growth of human breast cancer cells via the activation of CRH-R1 receptor subtype. 367
In vitro combined effects of human interferons and interleukin-2 on natural cell-mediated cytotoxicity 366
PARP1 is activated at telomeres upon G4 stabilization: possible target for telomere-based therapy 366
DNA damaging agents can induce celll cycle arrest in different phases of mitosis 366
null 366
Totale 40.677
Categoria #
all - tutte 139.871
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 139.871


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/20194.478 0 0 0 0 0 0 0 0 0 0 2.346 2.132
2019/202022.234 2.051 1.860 1.524 2.107 1.993 2.345 1.900 1.969 1.934 1.700 1.394 1.457
2020/202112.994 1.498 1.489 1.320 1.609 1.375 1.501 1.603 1.263 332 281 538 185
2021/20222.502 97 322 177 131 67 201 143 135 204 174 120 731
2022/20233.275 336 191 78 409 268 770 275 217 301 48 271 111
2023/20241.556 174 42 96 92 152 598 146 77 61 55 63 0
Totale 84.878